NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ultIMMa-1 and
Growth Capitalist (https://growthcapitalist.com/2018/02/abbvie-presents-new-positive-late-breaking-data-from-two-phase-3-psoriasis-trials-of-risankizumab-at-the-2018-american-academy-of-dermatology-annual-meeting/)
NORTH CHICAGO, Ill., Feb. 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today presented new positive results from the pivotal Phase 3 ultIMMa-1 and